SUBSCRIBE
SUBSCRIBE
News   Drug Development

Oxford BioMedica PLC Clarifies Trovax® Strategy

October 28, 2005 | 
1 min read

Oxford BioMedica (LSE: OXB), the leading gene therapy company, provides clarification of its strategy for its lead cancer immunotherapy, TroVax.

Clinical research Phase II Europe
MORE ON THIS TOPIC
candle flame and sparks home of the fireworks. In the center of the image of the heart"n
Editorial
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On
March 20, 2025
 · 
3 min read
 · 
Annalee Armstrong
Dorval, Quebec, Canada - September 3, 2021: Novartis Pharmaceuticals Canada Inc. head office building in Dorval, Quebec, Canada. Novartis is a global healthcare company based in Switzerland.
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
March 19, 2025
 · 
6 min read
 · 
Heather McKenzie
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Autoimmune disease
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
March 19, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hand shake icon on wooden cube block which connection with human icon for business deal and agreement concept.
Deals
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond
March 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky